Heparin suppresses lipid raft-mediated signaling and ligand-independent EGF receptor activation

Journal of Cellular Physiology

Volumn 211, Issue 1, 2007, Pages 205-212

  Liu, Yuan Tao ^a   Song, Lifang ^a   Templeton, Douglas M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CAVEOLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARAN SULFATE; HEPARIN; METHYL BETA CYCLODEXTRIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NYSTATIN; RAS PROTEIN; TYROSINE;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CELL MEMBRANE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REGULATION; LIPID RAFT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; BETA-CYCLODEXTRINS; CATTLE; CHOLESTEROL; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPARIN; LIGANDS; MEMBRANE MICRODOMAINS; NYSTATIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33847664697     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20924     Document Type: Article

References (70)

1. Anderson RGW. 1998. The caveolae membrane system. Annu Rev Biochem 67:199-225.
2. Aviezer D, Yayon A. 1994. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc Natl Acad Sci USA 91:12173-12177.
3. Brown DA, London E. 1998. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14:111-136.
4. Bàrzu T, Herbert J-M, Desmoulière A, Carayon P, Pascal M. 1994. Characterization of rat aortic smooth muscle cells resistant to the antiproliferative activity of heparin following long-term heparin treatment. J Cell Physiol 160:239-248.
5. Bârzu T, Pascal M, Maman M, Roque C, Lafont F, Rousselet A. 1996. Entry and distribution of fluorescent antiproliferative heparin derivatives into rat vascular smooth muscle cells: Comparison between heparin-sensitive and heparin-resistant cultures. J Cell Physiol 167:8-21.
6. Campbell L, Gumbleton M, Ritchie K. 2001. Caveolae and the caveolins in human disease. Adv Drug Delivery Rev 49:325-335.
7. Castellot JJ Jr, Karnovsky MJ. 1987. Heparin and the regulation of growth of the vascular wall. In: Campbell JH, Campbell GR, editors. Vascular Smooth Muscle in Culture. Boca Raton, FL:CRC Press. p 93-115.
8. Castellot JJ Jr, Cochran DL, Karnovsky MJ. 1985. Effect of heparin on vascular smooth muscle cells. I. Cell metabolism. J Cell Physiol 124:21-28.
9. Castellot JJ Jr, Choay J, Lormeau J-C, Petitou M, Sache E, Karnovsky M. 1986. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group. J Cell Biol 102:1979-1984.
10. Castellot JJ Jr, Pukac LA, Caleb BL, Wright TC Jr, Karnovsky MJ. 1989. Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells. J Cell Biol 109:3147-3155.
11. Cavari S, Ruggiero M, Vannucchi S. 1993. Antiproliferative effects of heparin on normal and transformed NIH/3T3 fibroblasts. Cell Biol Int 17:781-786.
12. Chen X, Resh MD. 2001. Activation of mitogen-activated protein kinase bymembrane-targeted Raf chimeras is independent of raft localization. J Biol Chem 276:34617-34623.
13. Chen X, Resh MD. 2002. Cholesterol depletion from the plasma membrane triggers ligand-independent activation of the epidermal growth factor receptor. J Biol Chem 277:49631-49637.
14. Cheng F, Petersson P, Arroyo-Yanguas Y, Westergren-Thorsson G. 2001. Differences in the uptake and nuclear localization of anti-proliferative heparan sulfate between human fung fibroblasts and human lung carcinoma cells. J Cell Biochem 83:597-606.
15. Christen T, Bochaton-Piallat ML, Neuville P, Rensen S, Redard M, Van Eys G, Gabbiani G. 1999. Cultured porcine coronary artery smooth muscle cells-A new model with advanced differentiation. Circ Res 85:99-107.
16. Couet J, Belanger MM, Roussel E, Drolet MC. 2001. Cell biology of caveolae and caveolin. Adv Drug Delivery Rev 49:223-235.
17. Daum G, Hedin U, Wang YX, Wang T, Clowes AW. 1997. Diverse effects of heparin on mitogen-activated protein kinase-dependent signal transduction in vascular smooth muscle cells. Circ Res 81:17-23.
18. de Rooij J, Bos JL. 1997. Minimal Ras-binding domain of Raf1 can be used as an activation specific probe for Ras. Oncogene 14:623-625.
19. Edelman ER, Karnovsky MJ. 1994. Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation 89:770-776.
20. kip1. J Biol Chem 280:15682-15689.
21. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP. 1998. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 17:6633-6648.
22. Garg HG, Thompson BT, Hales CA. 2000. Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. Am J Physiol 279:L779-L789.
23. Guyton JR, Rosenberg RD, Clowes AW, Karnovsky MJ. 1980. Inhibition of rat arterial smooth muscle cell proliferation by heparin. 1. In vivo studies with anticoagulant and non-anticoagulant heparin. Circ Res 46:625-634.
24. Haller H, Lindschau C, Quass P, Luft FC, Distler A. 1994. PDGF and Ang II induce differential spatial distribution of PKC-α and PKC-β in vascular smooth muscle cells. Hypertension 23:848-852.
25. Hnasko R, McFarland M, Ben-Jonathan N. 2002. Distribution and characterization of plasmalemma vesicle protein-1 in rat endocrine glands. J Endocrinol 175:649-661.
26. Kalmes A, Vesti BR, Daum G, Abraham JA, Clowes AW. 2000. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ Res 87:92-98.
27. Kazi M, Lundmark K, Religa P, Gouda I, Larm O, Ray A, Swedenborg J, Hedin U. 2002. Inhibition of rat smooth muscle cell adhesion and proliferation by non-anticoagulant heparins. J Cell Physiol 193:365-372.
28. Lambert S, Vind-Kezunovic D, Karvinen S, Gniadecki R. 2006. Ligand-independent activation of the EGFR by lipid raft disruption. J Invest Dermatol 126:954-962.
29. Letourneur D, Caleb BL, Castellot JJ Jr. 1995a. Heparin binding, internalization, and metabolism in vascular smooth muscle cells. I. Upregulation of heparin binding correlates with antiproliferative activity. J Cell Physiol 165:676-686.
30. Letourneur D, Caleb BL, Castellot JJ Jr. 1995b. Heparin binding, internalization, and metabolism in vascular smooth muscle cells. II. Degradation and secretion in sensitive and resistant cells. J Cell Physiol 165:687-695.
31. S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, Lisanti MP. 1995. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem 270:15693-15701.
32. S, Couet J, Lisanti MP. 1996. Src tyrosine kinases, Gα subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. J Biol Chem 271:29182-29190.
33. Libby P. 2002. Inflammation in atherosclerosis. Nature 220:868-874.
34. Lisanti MP, Sargiacomo M, Scherer PE. 1999. Purification of caveolae-derived membrane microdomains containing lipid-anchored signaling molecules, such as GPI-anchored proteins, H-Ras, Src-family tyrosine kinases, eNOS, and G-protein alpha-, beta-, and gamma-subunits. Methods Mol Biol 116:51-60.
35. Liu P, Ying Y, Ko Y, Anderson R. 1996. Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. J Biol Chem 271:10299-10303.
36. Mineo C, Ying YS, Chapline C, Jaken S, Anderson RG. 1998. Targeting of protein kinase Calpha to caveolae. J Cell Biol 141:601-610.
37. 2+/ calmodulin-dependent kinase II activation and c-fos induction in mesangial cells. Biochem J 330:651-657.
38. Miralem T, Wang A, Whiteside CI, Templeton DM. 1996. Heparin inhibits mitogen-activated protein kinase-dependent and-independent c-fos induction in mesangial cells. J Biol Chem 271:17100-17106.
39. Mishra-Gorur K, Castellot JJ Jr. 1999. Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells. J Cell Physiol 178:205-215.
40. Munro S. 2003. Lipid rafts: Elusive or illisive. Cell 115:377-388.
41. Murakami M, Nakatani Y, Kuwata H, Kudo I. 2000. Cellular components that functionally interact with signaling phospholipase A(2)s. Biochim Biophys Acta 1488:159-166.
42. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. 1998. Caveolins, a family of scaffolding proteinsfor organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 273:5419-5422.
43. Ottlinger ME, Pukac LA, Karnovsky MJ. 1993. Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells. J Biol Chem 268:19173-19176.
44. Patel RC, Handy I, Patel CV. 2002. Contribution of double-stranded RNA-activated protein kinase toward antiproliferative actions of heparin on vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 22:1439-1444.
45. Peterson TE, Kleppe LS, Caplice NM, Pan SC, Mueske CS, Simari RD. 1999. The regulation of caveolin expression and localization by serum and heparin in vascular smooth muscle cells. Biochem Biophys Res Commun 265:722-727.
46. Piepkorn M, Pittelkow MR, Cook PW. 1998. Autocrine regulation of keratinocytes: The emerging role of heparin-like, epidermal growth factor-related growth factors. J Ivest Dermatol 111:715-721.
47. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. 1999. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402:884-888.
48. Pukac LA, Castellot JJ Jr, Wright TC, Caleb BL, Karnovsky MJ. 1990. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Regulation 1:435-443.
49. Pukac LA, Carter JE, Ottlinger ME, Karnovsky MJ. 1997. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells. J Cell Physiol 172:69-78.
50. Ringerike T, Blystad FD, Levy FO, Madshus IH, Stang E. 2002. Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J Cell Sci 115:1331-1340.
51. Ross R. 1995. Cell biology of atherosclerosis. Annu Rev Physiol 57:791-804.
52. Rothman A, Kulik TJ, Taubman MB, Berk BC, Smith CWJ, Nadal-Ginard B. 1992. Development and characterization of a cloned ret pulmonary arterial smooth muscle cell line that maintains differentiated properties through multiple subcultures. Circulation 86:1977-1986.
53. Seger R, Krebs EG. 1995. The MAPK signaling cascade. FASEB J 9:726-735.
54. Shin JS, Abraham SN. 2001. Cell biology-Caveolae-Not just craters in the cellular landscape. Science 293:1447-1448.
55. Simons K, Toomre D. 2000. Lipid rafts and signal transduction. Nature Rev Mol Cell Biol 1:31-39.
56. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engleman JA, Scherer PE, Okamoto T, Lisanti MP. 1999. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 19:7289-7304.
57. Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP. 1996. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 271:9690-9697.
58. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. 1997. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 272:31730-31737.
59. Tamai O, Oka N, Kikuchi T, Koda Y, Soejima M, Wada Y, Fujisawa M, Tamaki K, Kawachi H, Shimizu F, Kimura H, Imaizumi T, Okuda S. 2001. Caveolae in mesangial cells and caveolin expression in mesangial proliferative glomerulonephritis. Kidney Int 59:471-480.
60. Templeton DM. 1992. Proteoglycans in cell regulation. CRC Crit Rev Clin Lab Sci 29:141-184.
61. Templeton DM, Zhao Y, Fan M-Y. 2000. Heterogeneity in the response of vascular smooth muscle to heparin: Altered signaling in heparin-resistant cells. Cardiovasc Res 45:503-512.
62. Thyberg J. 2000. Differences in caveolae dynamics in vascular smooth muscle cells of different phenotypes. Lab Invest 80:915-929.
63. Volpl N, Cusmano M, Venturelli T. 1995. Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim Biophys Acta 1243:49-58.
64. Wang A, Templeton DM. 1996. Inhibition of mitogenesis and c-fos expression in mesangial cells by heparin and heparan sulfates. Kidney Int 69:437-448.
65. Wang A, Fan M-Y, Templeton DM. 1994. Growth modulation and proteoglycan turnover in cultured mesangial cells. J Cell Physiol 159:295-310.
66. Wang Z, Chin TA, Templeton DM. 1996. Calcium-independent effects of cadmium on actin assembly in mesangial and vascular smooth muscle cells. Cell Motil Cytoskeleton 32:208-222.
67. Wang PY, Liu P, Weng J, Sontag E, Anderson RGW. 2003. A cholesterol-regulated PP2A/HePTP complex with dual specificity ERK1/2 phosphatase activity. EMBO J 22:2658-2667.
68. 2+/calmodulin- dependentprotein kinase II inhibition by heparin in mesangial cells. Am J Physiol 288:F142-F149.
69. Zarge JI, Huang P, Husak V, Kim DU, Haudenschild CC, Nord RM, Greisler HP. 1997. Fibrin glue containing fibroblast growth factor type I and heparin with autologous endothelial cells reduces intimal hyperplasia in a canine carotid artery balloon injury model. J Vasc Surg 25:840-848.
70. Zhao Y, Xiao W, Templeton DM. 2003. Suppression of mitogen-activated protein kinase phosphatase-1 (MKP-1) by heparin in vascular smooth muscle cells. Biochem Pharmacol 66:769-776.